Therapeutic radiopharmaceutical developer Angstrom Pharmaceuticals has won a patent for the treatment of metastatic cancer, according to research partner Diatide. The patent strengthens both companies’ efforts to develop anticancer therapeutic
Therapeutic radiopharmaceutical developer Angstrom Pharmaceuticals has won a patent for the treatment of metastatic cancer, according to research partner Diatide. The patent strengthens both companies efforts to develop anticancer therapeutic products.
In March, Diatide and Angstrom created a license agreement that gives Diatide exclusive rights to tumor imaging and anticancer therapeutics based on Angstroms uPAR (urokinase plasminogen activator receptor) targeting technology. The agreement stipulates that Diatide will pay Angstrom research and milestone payments, as well as royalties on product sales (SCAN 4/28/99). The firms are working together on research that combines Diatides peptide analog development expertise with Angstroms knowledge of uPAR-binding peptides.
UPAR is found on the surface of almost all solid tumors, including breast, prostate, colon, and lung. The two firms believe that targeting these receptors with radiotherapeutic agents could obstruct tumor growth. Angstroms latest patent covers a broad class of cyclic peptides that bind to uPAR.
In other Diatide news, the Londonderry, NH, companys NeoTect lung tumor agent has begun shipping. NeoTect received Food and Drug Administration clearance last month (SCAN 8/18/99). Diatide has a marketing partnership with Nycomed Amersham, although the Buckinghamshire, U.K., firm sold its share in the U.S. company in June (SCAN 6/23/99).
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.